Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

NCT04187898 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Neutropenia
Breast Cancer

Interventions

BIOLOGICAL: Eflapegrastim
BIOLOGICAL: Eflapegrastim
BIOLOGICAL: Eflapegrastim
BIOLOGICAL: Eflapegrastim
DRUG: Docetaxel
DRUG: Cyclophosphamide

Sponsor

Spectrum Pharmaceuticals, Inc